WPCS (WPCS) Awarded $16 Million in New Contracts

EXTON, PA — (Marketwire) — 04/18/12 — WPCS International Incorporated (NASDAQ: WPCS), a leader in design-build engineering services for communications infrastructure, has announced that it has received approximately $16 million in new contracts.

The new contracts include projects to be completed for Oxnard School District, Enfield Police Department, Styrolution America, Enfield Emergency Medical Services, CT Transit, MONOC, Bethlehem Volunteer Fire Department, Cranford Police Department, Siemens, Terman Middle School, University of California-Berkeley, NSTAR, Mount Wachusett Community College, New Brunswick Police Department, Manalapan Police Department, Ambulance Service of Manchester, Peoples Natural Gas and Duquesne Light. In Australia, new contracts were awarded for Holy Spirit Hospital, Narangba Railway Station, Rochedale Estates and Cherbourg Hospital. WPCS was also awarded a contract from the Taian Gas Group in China.

Myron Polulak, Executive Vice President of WPCS, commented, “As reported in the last quarter, WPCS had losses on a few projects which set us back. However, new contracts are being awarded to the company on a regular basis. Our reputation and workmanship remains at the highest level and customers continue to be satisfied with our services. As we continue to obtain new contracts, we believe that we will turnaround the recent performance and deliver much better results in the upcoming fiscal year.”

About WPCS International Incorporated:

WPCS is a design-build engineering company that focuses on the implementation requirements of communications infrastructure. The company provides its engineering capabilities including wireless communication, specialty construction and electrical power to the public services, healthcare, energy and corporate enterprise markets worldwide. For more information, please visit www.wpcs.com

Statements about the company’s future expectations, including future revenue and earnings and all other statements in this press release, other than historical facts, are “forward looking” statements and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward looking statements involve risks and uncertainties and are subject to change at any time. The company’s actual results could differ materially from expected results. In reflecting subsequent events or circumstances, the company undertakes no obligation to update forward looking statements.

CONTACT:

WPCS International Incorporated
610-903-0400 x101

THQ (THQI) Fiscal 2012 Fourth Quarter Results to Exceed Prior Expectations

THQ Inc. (NASDAQ: THQI) today provided preliminary, unaudited financial results for the fourth quarter ended March 31, 2012.

For the fourth quarter, THQ expects to report non-GAAP net sales of $160 million to $170 million, which is above the company’s previous outlook of non-GAAP net sales in the range of $130 million to $150 million. Revised net sales expectations reflect:

• continued strong net sales of the critically-acclaimed Saints Row^®: The Third^™, which to date has shipped in more than four million units;
• higher-than-expected digital sales, largely driven by the robust digital content of Saints Row: The Third; and
• slightly higher-than-expected net sales of UFC^® Undisputed^® 3, which was released mid-February 2012 to highly-favorable critical reviews, achieving an average Metacritic score of 85.

The company currently expects a fiscal fourth quarter non-GAAP net loss per share in the range of $0.10 to $0.20, compared to its previous expectation of a net loss per share in the range of $0.35 to $0.50.

THQ expects to report cash and cash equivalents of approximately $76 million at March 31, 2012, three times higher than the previous expectation for its year-end cash balance, due to better-than-expected operating results in the fourth quarter, as well as earlier-than-anticipated cash receipts. Additionally, the company ended the quarter with no outstanding borrowings on its $50 million credit facility, and did not borrow against the facility during the quarter. The company expects to utilize a substantial portion of its cash and cash equivalents as well as its credit facility as it launches its slate for the 2013 fiscal year, beginning with Darksiders^® II.

THQ’s GAAP results for the fourth quarter ended March 31, 2012 are expected to include non-cash software development charges of approximately $30 million to $50 million resulting from decisions made related to the company’s previously-announced product strategy.

THQ will report full GAAP and non-GAAP fiscal 2012 fourth quarter and full-year results, along with a reconciliation of those results, and provide its outlook for fiscal 2013 on Tuesday, May 15, 2012. Conference call details will be provided closer to the date.

About THQ

THQ Inc. (NASDAQ: THQI) is a leading worldwide developer and publisher of interactive entertainment software. The company develops its products for all popular game systems, personal computers, wireless devices and the Internet. Headquartered in Los Angeles County, California, THQ sells product through its global network of offices located throughout North America, Europe and Asia Pacific. More information about THQ and its products may be found at http://www.thq.com/. THQ, Darksiders, Saints Row, Saints Row: The Third and their respective logos are trademarks and/or registered trademarks of THQ Inc.

All other trademarks are property of their respective owners.

Non-GAAP Financial Measures

This press release discloses forward-looking information that includes expectations that are not presented in accordance with United States generally accepted accounting principles (“GAAP”). THQ believes that the use of non-GAAP financial measures provides meaningful supplemental information regarding its financial condition and results of operations, and helps investors compare actual results to its long-term operating goals as well as to its performance in prior periods. The non-GAAP financial measures included in the press release should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results.

THQ Inc. Caution Concerning Forward-Looking Statements

This press release contains statements that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations, estimates and projections about the business of THQ Inc. and its subsidiaries (collectively referred to as “THQ”), including, but not limited to, the company’s expectations for: its net sales and net loss for the fourth quarter ended March 31, 2012, its cash and cash equivalents at March 31, 2012, non-cash charges for the quarter ended March 31, 2012, and its future use of cash and borrowings under the company’s credit facility. These statements are based upon management’s current beliefs and certain assumptions made by management. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, business, competitive, economic, legal, political, and technological factors affecting our industry, operations, markets, products, or pricing. Readers should carefully review the risk factors and the information that could materially affect THQ’s financial results, described in other documents that THQ files from time to time with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal period ended March 31, 2011 and subsequent Quarterly Reports on Form 10-Q, and particularly the discussion of trends and risk factors set forth therein. Unless otherwise required by law, THQ disclaims any obligation to update its view on any such risks or uncertainties or to revise or publicly release the results of any revision to these forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

AMRI (AMRI) Announces Development and Manufacturing Deal with Biota Holdings Limited

Innotrac (INOC) Shares Findings of February eCommerce Benchmarking Study

ATLANTA, April 17, 2012 /PRNewswire/ — Innotrac Corporation (NASDAQ: INOC), a best-of-breed commerce provider integrating digital technology, fulfillment, and contact center solutions to support global brands, today announced summary results of its latest SmartHub® e-commerce benchmark analysis, which was based on a sampling of orders placed in February of this year.

SmartHub® is Innotrac’s research and strategy layer, providing clients and partners with consultative services, including end-to-end intelligence of the online retail purchase cycle. From the pre-order site experience all the way through the final steps of the returns process, Innotrac’s 56-point methodology analyzes each important customer touch point, charting retailers on everything from the checkout experience, to evaluation of the packaging material used in shipment. SmartHub® also encompasses custom research and analysis available for current clients who are confronting the challenges of building and nurturing their eCommerce channel.

“The continued expansion of SmartHub® is reflective of our efforts to be a true strategic partner for our clients,” said Jon Eggleton, Innotrac’s Vice President of Marketing & eCommerce. “They expect us to be more than just a fulfillment and contact center solutions provider, and SmartHub® is one way in which we can add more value to those relationships.”

SmartHub® evaluated 100 leading U.S. e-retailers across six different product categories in February for its latest report, SmartHub® release 2.0. Among the findings:

• The average number of checkout pages required to complete an order was three; only 7% of merchants surveyed offered one-page checkout as an option.
• 96% of merchants surveyed were able to confirm inventory of a purchased item through customer service, however, of those who had more than one distribution channel (e.g. online plus physical stores, or catalog), only 47% of CSRs appeared to have visibility into activity happening outside of the e-commerce or direct channel.
• 65% of all merchants surveyed were able to ship packages to customers in three days or less, a slight improvement from the busy Q4 holiday season. Merchants in the Housewares/Home category were most expedient, with 74% of orders received within three business days.
• 38% of all merchants utilized some sort of branded packaging, either inside or outside the box, up from 29% in Q4. Health/Beauty merchants were most aggressive, with 53% utilizing branded packaging, the only category in the survey that indexed higher than 50%.

The addition of several new data points, including those pertaining to customer service, has provided additional insights not seen in previous SmartHub® releases. Multi-channel visibility is one such area that is now being evaluated as retailers become more proficient at servicing customers who see no boundaries between online and brick-and-mortar outlets.

“It is particularly interesting that a slight majority of merchants aren’t yet providing omni-channel activity to customers through one source,” said Eggleton. “We expect to see this trend change as customers push further for channel transparency.”

About Innotrac

Innotrac (NASDAQ: INOC) was founded in 1984, with the goal of providing the highest quality fulfillment services to both our clients and their customers. We have an integrated network of eight fulfillment centers, along with a contact center in North America. Innotrac Europe GmbH has a network of fulfillment centers, call centers, and returns processing facilities with operations in the UK, Germany, France, Denmark, Sweden, Poland, Austria, Italy, Switzerland, Ireland, Spain and the Netherlands. Connect with Innotrac at www.innotrac.com or http://www.linkedin.com/company/innotrac.

Media Contact:

Yolanda Kokayi
Innotrac Marketing Manager
678-584-4096
ykokayi@innotrac.com

Information contained in this press release, other than historical information, may be considered forward-looking in nature. Forward-looking statements are subject to various risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, estimated or expected. Among the key factors that may have a direct bearing on Innotrac’s operating results, performance or financial condition are competition, the demand for Innotrac’s services, Innotrac’s ability to retain its current clients, Innotrac’s success in growing its existing client base, developing new business, Innotrac’s ability to maintain or improve gross margins in the face of increasing revenues, reducing operating costs in response to reduced service revenues, realization of expected revenues from new clients, the general state of the industries that the Company serves, changing technologies, Innotrac’s ability to maintain profit margins in the face of pricing pressures and numerous other factors discussed in Innotrac’s 2011 Annual Report on Form 10-K and other filings on file with the Securities and Exchange Commission. Innotrac disclaims any intention or obligation to update or revise any forward-looking statement whether as a result of new information, future events or otherwise.

BioDelivery Sciences (BDSI) Awarded Patent Resulting in $15 Million Milestone Payment

RALEIGH, N.C., April 17, 2012 /PRNewswire/ — BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that the U.S. Patent and Trademark Office (USPTO) has formally awarded BDSI’s patent No. 13/184306, “Transmucosal Delivery Devices with Enhanced Uptake,” which extends the patent protection for BDSI’s BioErodible MucoAdhesive (BEMA) products, BEMA Buprenorphine and BEMA Buprenorphine/Naloxone, by seven years to 2027. The USPTO had issued a Notice of Allowance to BDSI for this patent as previously disclosed in February of this year.

(Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO )

BDSI now confirms that the $15 million milestone associated with its licensing and development agreement with Endo Pharmaceuticals for BEMA Buprenorphine is payable, bringing the total milestone payments received thus far to $45 million.

About BioDelivery Sciences International

BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics. BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and oncology supportive care. BDSI’s pain franchise currently consists of two products utilizing the patented BEMA technology. ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, and the E.U. (where it will be marketed as BREAKYL), for the management of breakthrough pain in opioid tolerant, adult patients with cancer. The commercial rights are licensed to Meda for all territories worldwide except for Taiwan (licensed to TTY Biopharm) and South Korea (licensed to Kunwha Pharmaceutical Co.). BDSI’s second pain product, BEMA Buprenorphine, is being developed for the treatment of moderate to severe chronic pain and is in development in a high dose formulation with naloxone for the treatment of opioid dependence. BEMA Buprenorphine for chronic pain is licensed on a worldwide basis to Endo Pharmaceuticals. Additional product candidates are being developed utilizing the BEMA technology for conditions such as nausea/vomiting (BEMA Granisetron). BDSI’s headquarters is located in Raleigh, North Carolina. For more information, visit www.bdsi.com.

BDSI® and BEMA® are registered trademarks of BioDelivery Sciences International, Inc. ONSOLIS® is a registered trademark of Meda Pharmaceuticals, Inc. BREAKYL is registered trademark of Meda Pharma GmbH & Co. KG.

Cautionary Note on Forward-Looking Statements

This press release and any statements of representatives and partners of BioDelivery Sciences International, Inc. (the “Company”) related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results (including, without limitation, the results of the Company’s development initiatives with, and potential future royalties from, BEMA Buprenorphine and BEMA Buprenorphine/Naloxone) may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Readers are cautioned that peak sales and market size estimates have been determined on the basis of market research and comparable product analysis, but no assurances can be given that such estimates are accurate or that such sales levels will be achieved, if at all.

SOURCE BioDelivery Sciences International, Inc.

GlobalWise (GWIV) Announces Channel Sales Partnership With FormFast

COLUMBUS, OH — (Marketwire) — 04/17/12 — GlobalWise Investments, Inc. (OTCBB: GWIV) (OTCQB: GWIV) (www.GlobalWiseInvestments.com) and its wholly owned subsidiary Intellinetics, Inc., a leading-edge technology company focused on the design, implementation and management of cloud-based Enterprise Content Management (“ECM”) systems in both the public and private sectors, today announce a Channel Sales Partnership has been executed with FormFast.

Since 1992, FormFast (www.formfast.com) has been the recognized leader in e-forms software that has enabled healthcare organizations to achieve significant process improvement across the enterprise. With custom workflow solutions ranging from HR, contract management, risk management and compliance, FormFast is the top-ranked workflow provider for over 950 high performance hospitals in achieving their goal of being paperless.

“We are very pleased to announce our partnership with Intellinetics and the addition of the Intellivue™ ECM Solution to our product portfolio,” said Rob Harding, CEO of FormFast. “Intellivue™ will help us expand in several key markets where we already have a presence. Intellivue™ has focused on tight integration with key line-of-business applications, with an aggressive pricing strategy that fits a wide range of our healthcare customers.”

“By partnering with Intellinetics, FormFast expands their product portfolio to include an affordable, cloud-based ECM solution for healthcare providers,” stated William. J. “BJ” Santiago, CEO of GlobalWise. “We expect this relationship will open many new doors in the healthcare industry for Intellinetics. FormFast has an extensive hospital and healthcare provider network of clients who have a primary need to implement an affordable ECM solution like Intellivue™. Channel Partnerships such as this one are a key component in our growth strategy and I expect to see multiple new healthcare client relationships as a result of this exciting new Channel Partner.”

“Healthcare organizations are very cost conscious and we believe the Intellivue™ platform is the perfect fit for organizations whose budget limitations fall within a range of $60,000 to $100,000 for an ECM solution. I look forward to working with FormFast to generate new sales opportunities in the coming months,” concluded Mr. Santiago.

About FormFast

FormFast is a veteran and leader in the Document Automation field and is continuously expanding their product portfolio to deliver the most complete document automation and management solutions. FormFast’s technology is designed to improve business processes, streamline workflows, and increase overall efficiency in your business. Our business partnerships ensure the highest level of support and integration regardless of your technology. The FormFast solutions are scalable and flexible enough to meet the needs any size organization. Regardless of where you are on the path to electronic documentation, FormFast has the experience, the people, and world-class customer service to make the transition successful. For additional information, please visit the Company’s corporate website: www.formfast.com

About GlobalWise Investments, Inc.

GlobalWise Investments, Inc., via its wholly owned subsidiary Intellinetics, Inc., is a Columbus, Ohio based Enterprise Content Management (ECM) pioneer with industry-leading software that delivers cloud ECM based solutions on-demand. The Company’s flagship platform, Intellivue™, represents a new industry benchmark and game-changing solution by enabling clients to access and manage the content of every scanned document, file, spreadsheet, email, photo, audio file or video tape – virtually anything that can be digitized – in their enterprise from any PC, laptop, tablet or smartphone from anywhere in the world.

For additional information, please visit the Company’s corporate website: www.GlobalWiseInvestments.com

This press release may contain “forward-looking statements.” Expressions of future goals and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements may include, without limitation, statements about our market opportunity, strategies, competition, expected activities and expenditures as we pursue our business plan. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot predict the effect that market conditions, customer acceptance of products, regulatory issues, competitive factors, or other business circumstances and factors described in our filings with the Securities and Exchange Commission may have on our results. The company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this press release.

GlobalWise Investments, Inc.
www.GlobalWiseInvestments.com
614-388-8909
Contact@GlobalWiseInvestments.com

Mission Investor Relations
Atlanta, Georgia
http://www.MissionIR.com
404-941-8975
Investors@MissionIR.com

SEFE, Inc. (SEFE) Highlights Patent for Strain Reduction System

SEFE, Inc. (OTCBB: SEFE.OB) (“SEFE”) (“The Company”) today offered further details on its pending patent for Strain Reduction On A Balloon System In Extreme Weather Conditions.

SEFE’s breakthrough Harmony III unit is designed to collect atmospheric energy under a wide range of conditions. During inclement weather, of course, the system is subjected to higher forces, and SEFE engineers have developed and are testing a number of mechanisms and innovations to maintain safety and integrity while continuing to generate electricity.

In layman’s terms, the patent-pending strain reduction system is achieved by using an elastic bungee between a balloon and the tether attached to the balloon. As wind pushes on the balloon, immediate pressure caused by the wind is absorbed by the elastic bungee rather than the balloon or the tether, thereby reducing immediate force and tension and protecting the components from damage. The patent for the strain reduction device was filed with the U.S. Patent and Trademark Office as application #13/103,988 on May 9, 2011.

“We appreciate each piece of intellectual property developed by our team as an additional protection of value for our shareholders,” said Don Johnston, SEFE’s CEO. “One of our goals is to build ownership around our core technology, in order to protect our position within this space. This particular patent is related to our Harmony unit’s ability to withstand the elements while doing its job collecting atmospheric electricity.”

For more information visit www.SEFElectric.com.

About SEFE, Inc.

SEFE focuses on pushing the boundaries of what’s possible, embracing innovation and employing the cutting-edge to solve problems, and offering sustainable solutions to a world hungry for invention, direction and leadership. SEFE is technology- and solutions-driven, focusing on developing inventions that provide a real-world impact and true profitability. So, success is measured by both a sustainable return on investment, as well as a project’s sustainability from an environmental perspective.

For more information, visit www.SEFElectric.com.

Forward-Looking Statements

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

SEFE (SEFE) Moves Headquarters to Boulder, Colo.

SEFE, Inc. (OTCBB: SEFE) (“SEFE”) (“The Company”) today announced that its corporate headquarters will be relocated to Boulder, Colo., effective immediately.

The move serves a strategic purpose, simplifying operations by bringing the headquarters to the Company’s recently opened Science and Technology Center, also in Boulder. The two announcements come as SEFE ramps up its testing plans, including the proprietary atmospheric energy detection system that will begin during Q2 2012.

“The Arizona office served its purpose as a low-cost, easily accessed location during the startup phase of the Company, but was never intended to be a permanent solution,” said SEFE CEO Don Johnston. “Now that we are taking design, testing, and commercialization to the next level, having the lab and the corporate headquarters in close proximity in Boulder should prove to be a major benefit.”

The Company’s new corporate headquarters address will be 4700 Sterling Dr., Boulder, CO 80301.

For more information, visit www.SEFElectric.com.

About SEFE, Inc.

SEFE focuses on pushing the boundaries of what’s possible, embracing innovation and employing the cutting-edge to solve problems, and offering sustainable solutions to a world hungry for invention, direction and leadership. SEFE is technology- and solutions-driven, focusing on developing inventions that provide a real-world impact and true profitability. So, success is measured by both a sustainable return on investment, as well as a project’s sustainability from an environmental perspective.

For more information, visit www.SEFElectric.com.

Forward-Looking Statements

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

VistaGen (VSTA) Licenses Breakthrough Stem Cell Culture Technology

SOUTH SAN FRANCISCO, CA — (Marketwire) — 04/16/12 — VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue and cell therapy, has licensed breakthrough stem cell culture technology from the McEwen Centre for Regenerative Medicine located at the University Health Network (UHN) in Toronto, Canada.

VistaGen will be utilizing the licensed technology to develop hematopoietic precursor stem cells from human pluripotent stem cells, with the goal of developing drug screening and cell therapy applications for human blood system disorders. The breakthrough technology is included in a new United States patent application.

Hematopoietic precursor stem cells give rise to all red and white blood cells and platelets in the body. VistaGen will use the UHN invention to improve the cell culture methods used to efficiently produce hematopoietic stem cell populations.

“This technology dramatically advances our ability to produce and purify this important blood stem cell precursor for both in vitro drug screening and in vivo cell therapy applications,” said H. Ralph Snodgrass, PhD, VistaGen’s President and Chief Scientific Officer.

“In addition to defining new cell culture methods for our use, the technology describes the surface characteristics of stem cell-derived adult hematopoietic stem cells. Most groups study embryonic blood development from stem cells, but, for the first time, we are able to not only purify the stem cell-derived precursor of all adult hematopoietic cells, but also pinpoint the precise timing when adult blood cell differentiation takes place in these cultures,” Snodgrass added. “It is our belief that these early cells will be the precursors of the ultimate adult, bone marrow-repopulating hematopoietic stem cells.”

Bone marrow-derived hematopoietic stem cells are able to repopulate the blood and immune system when transplanted into patients prepared for bone marrow transplantation. These cells have important potential therapeutic applications for the restoration of healthy blood and immune systems in individuals undergoing transplantation therapies for cancer, organ grafts, HIV infections or for acquired or genetic blood and immune deficiencies.

About VistaGen Therapeutics

VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue and cell therapy. VistaGen’s drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube™, with modern medicinal chemistry to generate new chemical variants (Drug Rescue Variants) of once-promising small-molecule drug candidates. These are drug candidates discontinued due to heart toxicity after substantial development by pharmaceutical companies, the U.S. National Institutes of Health (NIH) or university laboratories. VistaGen uses its pluripotent stem cell technology to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates before they are ever tested in humans, bringing human biology to the front end of the drug development process.

Additionally, VistaGen’s small molecule drug candidate, AV-101, is in Phase 1b development for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects approximately 1.8 million people in the U.S. alone. VistaGen is also exploring opportunities to leverage its current Phase 1 clinical program to enable additional Phase 2 clinical studies of AV-101 for epilepsy, Parkinson’s disease and depression. To date, VistaGen has been awarded over $8.5 million from the NIH for development of AV-101.

Visit VistaGen at http://www.VistaGen.com, follow VistaGen at http://www.twitter.com/VistaGen or view VistaGen’s Facebook page at http://www.facebook.com/VistaGen

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals, the issuance and protection of patents and other intellectual property, the success of VistaGen’s ongoing clinical studies, including the safety and efficacy of its drug candidate, AV-101, the failure of future drug rescue and pilot preclinical cell therapy programs related to VistaGen’s stem cell technology-based Human Clinical Trial in a Test Tube™ platform, its ability to enter into drug rescue collaborations, risks and uncertainties relating to the availability of substantial additional capital to support VistaGen’s research, development and commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to AV-101 and any drug rescue variants identified and developed by VistaGen. These and other risks and uncertainties are identified and described in more detail in VistaGen’s filings with the Securities and Exchange Commission (SEC). These filings are available on the SEC’s website at www.sec.gov. VistaGen undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:

Shawn K. Singh, J.D.
Chief Executive Officer
VistaGen Therapeutics, Inc.
www.VistaGen.com
650-244-9990 x224
Investor.Relations@VistaGen.com

Mission Investor Relations
Atlanta, Georgia
http://www.MissionIR.com
404-941-8975
Investors@MissionIR.com

USA Technologies (USAT) Announces Preliminary Third Quarter Fiscal 2012 Results

USA Technologies, Inc. (NASDAQ: USAT), (“USAT”), a leader of wireless, cashless payment and M2M telemetry solutions for small-ticket, self-serve retailing industries, today announced the following preliminary information for the third quarter of fiscal year 2012 ended March 31, 2012.

• Total Revenues for the third quarter are expected to be approximately $7.5 million, reflecting an increase of approximately 36% from the same period in the prior year.
• Recurring revenues for the third quarter are expected to be approximately $5.9 million, an increase of approximately 39% from the third quarter of fiscal 2011. Recurring revenues, which represented approximately 79% of total revenues for the third quarter, are comprised of ePort Connect® license fees and transaction processing fees per connection as well as rental revenues from USA Technologies’ JumpStart program.
• Total connections added in the quarter, which contribute to future recurring revenues, were approximately 12,000, an increase of 304% from the same period a year ago. The growth in connections was fueled by USAT’s JumpStart program, expansion into vertical markets such as kiosk and continued demand for cashless payment solutions to meet consumer’s desire for non-cash options. Based on preliminary additional connections of 12,000 for the quarter, USAT’s total connected base now stands at approximately 148,000, a 32% increase from the same period one year ago.
• Adjusted EBITDA is expected to be approximately $300,000 for the third quarter of fiscal 2012, compared to an Adjusted EBITDA loss of $(940,170) for the third quarter of fiscal 2011.

“When we communicated our priorities to shareholders in late 2011, we indicated that our top priority was to drive the business toward profitability,” said Stephen P. Herbert, Chairman and CEO of USA Technologies. “We also said that the first milestone in reaching that goal was achieving positive and sustainable Adjusted EBITDA. Given these goals, we are extremely pleased with our progress. We achieved positive Adjusted EBITDA in each and every month this quarter, evidence that the steps we have taken to streamline expenses are taking hold and our business model is beginning to yield the recurring revenue base necessary to fund our future growth. These positive indicators combined with our growing connected service base and the various growth initiatives underway, point to the strong commitment of USAT’s Board of Directors and management team in driving shareholder value.

“Consumers are clearly moving toward cashless payment including credit, debit and mobile payment options. We want our customers to participate in this exciting industry trend and our growth platforms reflect that commitment. We are driving adoption in the largely untapped traditional vending market, leveraging opportunities in vertical markets like kiosk, and we are working to expand our services offerings, some of which will be introduced to customers at trade shows and marketing events later in the month, said Herbert.”

The third quarter fiscal 2012 financial results included in this release are preliminary and subject to finalization of USA Technologies’ quarterly financial and accounting procedures. USA Technologies will hold a conference call and Webcast to review its third quarter fiscal 2012 financial results in early May. Details will be released approximately two weeks prior to the call.

Non-GAAP Financial Measures: Adjusted EBITDA

This press release includes the following financial measure defined as a non-GAAP financial measure by the Securities and Exchange Commission: Adjusted EBITDA. See “Reconciliation of GAAP Net Earnings (Loss) to Adjusted Earnings (Loss) Before Interest, Taxes, Depreciation and Amortization Expense (Adjusted EBITDA)” table in this press release for further information regarding this non-GAAP financial measure.

As used herein, Adjusted EBITDA represents net income (loss) before interest income, interest expense, income taxes, depreciation, amortization, and change in fair value of warrant liabilities and stock-based compensation expense. We have excluded the non-operating item, change in fair value of warrant liabilities, because it represents a non-cash charge that is not related to USAT’s operations. We have excluded the non-cash expense, stock-based compensation, as it does not reflect the cash-based operations of USAT. Adjusted EBITDA is a non-GAAP financial measure which is not required by or defined under GAAP (Generally Accepted Accounting Principles). The presentation of this financial measure is not intended to be considered in isolation or as a substitute for the financial measures prepared and presented in accordance with GAAP, including the net income or net loss of USAT or net cash used in operating activities. Management recognizes that non-GAAP financial measures have limitations in that they do not reflect all of the items associated with USAT’s net income or net loss as determined in accordance with GAAP, and are not a substitute for or a measure of USAT’s profitability or net earnings. Adjusted EBITDA is presented because we believe it is useful to investors as a measure of comparative operating performance and liquidity, and because it is less susceptible to variances in actual performance resulting from depreciation and amortization and non-cash charges for changes in fair value of warrant liabilities and stock-based compensation expense.

Reconciliation of GAAP Net Earnings (Loss) to Adjusted Earnings (Loss) Before Interest, Taxes, Depreciation and Amortization (Adjusted EBITDA)

A reconciliation of the preliminary GAAP net earnings (loss) to preliminary Adjusted EBITDA is provided below. USAT will provide a final reconciliation of GAAP net earnings (loss) to Adjusted EBITDA for the third quarter ended March 31, 2012 when USAT issues its full results.

About USA Technologies:

USA Technologies is a leader in the networking of wireless non-cash transactions, associated financial/network services and energy management. USA Technologies provides networked credit card and other non-cash systems and services in the vending, commercial laundry, hospitality and digital imaging industries. The company has been granted 79 patents and has agreements with Verizon, Visa, Compass, Crane and others. Visit our website at www.usatech.com

Forward-looking Statements:

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: All statements other than statements of historical fact included in this release, including without limitation the financial position, achieving profitability, business strategy and the plans and objectives of USAT’s management for future operations, are forward-looking statements. When used in this release, words such as “anticipate”, “believe”, “estimate”, “expect”, “intend”, and similar expressions, as they relate to USAT or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of USAT’s management, as well as assumptions made by and information currently available to the USAT’s management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to, the ability of USAT to generate sufficient sales to generate operating profits, or conduct operations at a profit; the ability of USAT to retain key customers from whom a significant portion of its revenues is derived; whether USAT’s customers continue to operate or commence operating ePorts received under the Jumpstart program or otherwise at levels currently anticipated by USAT; the ability of USAT to compete with its competitors to obtain market share; whether USAT’s customers continue to utilize USAT’s transaction processing and related services, as our customer agreements are generally cancelable by the customer on thirty to sixty days’ notice; whether the significant increase in the interchange fees to be charged by Visa and MasterCard for small ticket debit card transactions would adversely affect our business, including our revenues, gross profits, and anticipated future connections to our network; whether or not accepting any MasterCard debit cards effective mid-November 2011 would adversely affect our business, including our revenues, gross profits, and anticipated future connections to our network; and, whether USAT’s existing or anticipated customers purchase ePort devices in the future at levels currently anticipated by USAT. Readers are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statement made by us in this release speaks only as of the date of this release. Unless required by law, USAT does not undertake to release publicly any revisions to these forward-looking statements to reflect future events or circumstances or to reflect the occurrence of unanticipated events.

Fanatics to Acquire Dreams (DRJ) for $3.45 per Share

Dreams, Inc. (NYSE Amex: DRJ), a technology-driven, multi-channel retailer focused on the licensed sports products industry, has signed a definitive merger agreement with Fanatics, Inc., a leading online seller of licensed sports products.

The agreement calls for Fanatics to acquire all the outstanding shares of the company for $3.45 per share in cash for an aggregate transaction value of approximately $183 million, taking into account $25 million of outstanding debt. The offer represents a premium of 32.0% over Dreams’ closing share price of $2.61 on April 13, 2012, the last trading day prior to this announcement.

The Board of Directors of Dreams has unanimously approved the transaction, which is subject to customary closing conditions, including the approval of Dreams’ shareholders and regulatory approvals. The transaction is expected to close in the third quarter of 2012.

Dreams President and CEO Ross Tannenbaum, Chairman Sam Battistone and other shareholders who collectively own approximately 35% of the outstanding shares of Dreams have each entered into voting and support agreements by which they have committed to vote in favor of the proposed merger transaction.

“Fanatics shares our focus on the customer, innovation, and growth,” said Ross Tannenbaum. “This combination will enhance Dreams’ ability to achieve its goals, while realizing a significant and immediate all-cash premium for our shareholders. I am confident this merger is the right decision for Dreams and our shareholders.”

Dr. Phillip Frost, Dreams’ third largest shareholder, Chairman of Teva Pharmaceuticals (NYSE:TEVA) and Chairman and CEO of Opko (NYSE:OPKO), commented: “Ross and his executive team have built a terrific company and ultimately were able to deliver meaningful value to all of its shareholders.”

“Today is an exciting day for all sports fans,” said Fanatics’ CEO Alan Trager. “We are bringing together two of the most passionate management teams in licensed sports products. The addition of Dreams will enable Fanatics to accelerate our investments in product assortment, mobile and e-commerce technology, and a regional fulfillment infrastructure to better serve our customers and our partners. Together, we will be much better positioned to deliver a superior customer experience.”

In conjunction with the acquisition, Fanatics entered into definitive equity financing with Insight Venture Partners.

Jefferies & Company, Inc. acted as the exclusive financial advisor and Roetzel & Andress, LPA served as legal advisor to Dreams. Morgan, Lewis & Bockius LLP served as legal adviser to Fanatics, Inc.

About Fanatics, Inc.

Fanatics provides e-commerce, merchandising, marketing and fulfillment services for professional sports leagues and teams, collegiate athletic programs and conferences, and other major sports properties. Offering broad assortments online consisting of hundreds of thousands of officially licensed items, Fanatics leverages both its large network of partners and its own collection of proprietary brands to distribute goods to consumers all over the world. www.fanatics.com.

About Dreams, Inc.

Dreams, Inc. (NYSE Amex: DRJ) is a technology driven, multi-channel retailer focused on the sports licensed products industry. For more information, please visit www.Dreamscorp.com.

Forward Looking Statements:

This release contains forward-looking statements, including those regarding the proposed transaction. These statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including but not limited to: the ability of the parties to consummate the proposed transaction in a timely manner or at all; the satisfaction of conditions precedent to consummation of the Transaction, including the ability to secure regulatory approvals and approval by Dreams shareholders; the possibility of litigation (including litigation related to the transaction itself); and other risks described in Dreams, Inc.’s filings with the Securities and Exchange Commission (the “SEC”), including its most recent Form 10-K. All forward-looking statements are based on management’s estimates, projections and assumptions as of the date hereof, and Dreams does not undertake any obligation to update any forward-looking statements.

Additional Information and Where to Find It:

In connection with the proposed transaction and required stockholder approval, the Company will file a proxy statement with the SEC. INVESTORS AND SECURITY HOLDERS ARE ADVISED TO READ THE PROXY STATEMENT AND OTHER RELEVANT MATERIALS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT DREAMS AND THE TRANSACTION. Investors and Security holders may obtain free copies of these documents (when they are available) and other documents filed with the SEC at the SEC’s web site at www.sec.gov. In addition, the documents filed by Dreams with the SEC may be obtained free of charge by contacting Dreams, Inc. by mail at Dreams, Inc., 2 South University Drive, Plantation, Florida 33324, Attn: Corporate Secretary. The Company’s filings with the SEC are also available on Dreams’ website at: www.Dreamscorp.com.

Participants in the Solicitation

Dreams and its directors and executive officers may be deemed to be participants in the solicitation of proxies from Dreams’ shareholders in connection with the proposed transaction. Information about Dreams’ directors and executive officers is set forth in Dreams, Inc.’s Proxy Statement for its 2011 Annual Meeting of Stockholders, which was filed with the SEC on November 2, 2011 and its Annual Report on Form 10-K for the year ended December 31, 2011, which was filed with the SEC on March 29, 2012. These documents are available free of charge at the SEC’s website at www.sec.gov, and from Dreams, Inc. by contacting Dreams by mail at 2 South University Drive, Plantation, Florida 33324, Attn: Corporate Secretary. Additional information regarding the interests of participants in the solicitation of proxies in connection with the transaction will be included in the proxy statement that Dreams intends to file with the SEC.

TV Recording Feature Added to Broadway, Hauppauge’s (HAUP) TV Streamer

Quantum Technologies (QTWW) Announces Repayment of Senior Secured Debt

IRVINE, Calif., April 12, 2012 /PRNewswire/ — Quantum Technologies, Inc. (the “Company”) (Nasdaq: QTWW), announced today that it has fully repaid all of the outstanding indebtedness owed to its senior secured lender and, as a result of such repayment, the Credit Agreement between the Company and its senior secured lender has been terminated.

“We are extremely pleased to have fully repaid the debt obligations owed to our senior secured lender,” said Alan P. Niedzwiecki, President and CEO of Quantum. Mr. Niedzwiecki added, “Over the past twelve months, we have significantly improved our balance sheet by reducing our debt by approximately $13.5 million. Going forward, we can direct our resources on executing and expanding on our natural gas and hybrid vehicle programs as well as other business opportunities.”

About Quantum
Quantum Fuel Systems Technologies Worldwide, Inc., a fully integrated alternative energy company, is a leader in the development and production of advanced propulsion systems, natural gas vehicle storage technologies, and alternative fuel vehicles. Quantum’s wholly owned subsidiary, Schneider Power Inc., and affiliate, Asola Solarpower GmbH, complement Quantum’s emerging renewable energy presence through the development and ownership of wind and solar farms, and manufacture of high efficiency solar modules. Quantum’s portfolio of technologies includes electronic controls, hybrid electric drive systems, natural gas and hydrogen storage and metering systems and alternative fuel technologies that enable fuel efficient, low emission hybrid, plug-in hybrid electric, fuel cell, and natural gas vehicles. Quantum’s powertrain engineering, system integration, vehicle manufacturing, and assembly capabilities provide fast-to-market solutions to support the production of hybrid and plug-in hybrid, hydrogen-powered hybrid, fuel cell, natural gas fuel, and specialty vehicles, as well as modular, transportable hydrogen refueling stations. Quantum’s customer base includes automotive OEMs, dealer networks, fleets, aerospace industry, military and other government entities, and other strategic alliance partners.

Forward Looking Statements:
This press release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements included in this report, other than those that are historical, are forward-looking statements and can generally be identified by words such as “may,” “could,” “will,” “should,” “assume,” “expect,” “anticipate,” “plan,” “intend,” “believe,” “predict, ” “estimate,” “forecast,” “outlook,” “potential,” or “continue,” or the negative of these terms, and other comparable terminology. Various risks and other factors could cause actual results, and actual events that occur, to differ materially from those contemplated by the forward looking statements. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.

More information can be found about the products and services of Quantum, Schneider Power and Asola at http://www.qtww.com/ or you may contact:

©2012 Quantum Fuel Systems Technologies Worldwide, Inc.
17872 Cartwright Road, Irvine, CA 92614
Phone 949-399-4500 Fax 949-399-4600

Mantra (MVTG) Welcomes Tom Unger as VP of Corporate Finance

Southcoast (SOCB) Announces First Quarter Earnings

MT. PLEASANT, S.C., April 12, 2012 (GLOBE NEWSWIRE) — Southcoast Financial Corporation (Nasdaq:SOCB) announced that it had unaudited net income of $1,243,000, or $0.23 per basic share, for the quarter ended March 31, 2012. This compares to unaudited net loss of $579,000, or $0.11 per basic share, for the quarter ended March 31, 2011. The March 31, 2012 income per share is based on 5,316,633 basic average shares compared to 5,270,053 basic average shares for the first quarter of 2011.

“The first quarter’s results were impacted by a decrease in operating expenses, gains on the sale of impaired assets, security gains and a reduction in our loan loss provision,” said L. Wayne Pearson, Chairman and Chief Executive Officer. “While we continue to work diligently on improving our asset quality, we continue to maintain strong capital levels and are encouraged by an improvement in our net core earnings over the quarter ended March 31, 2011.”

Net interest income decreased $56,000 from $3,233,000 for the first quarter of 2011 to $3,177,000 for the first quarter of 2012. A reduction in interest income due to volume decreases in average loans and securities was almost completely offset by the reduction of interest cost as existing liabilities repriced. The Company’s annualized net interest margin improved by 19 basis points to 3.46% for the first quarter of 2012 from 3.27% for the first quarter of 2011, due to the significant reduction in our cost of funds.

Noninterest income increased to $906,000 for the first quarter of 2012 from $342,000 for the first quarter of 2011, primarily due to $215,000 of securities gains and $124,000 of gains on sales of fixed assets during the first quarter of 2012, compared to securities gains of $21,000 and no gains on sales of fixed assets during the first quarter of 2011. Non-interest income levels for the quarter ended March 31, 2011 also included a $176,000 other-than-temporary impairment charge on an investment security. The amount of securities gains and other-than-temporary impairment charges may fluctuate significantly between periods.

Noninterest expense levels decreased to $2,652,000 for the quarter ended March 31, 2012 from $3,428,000 for the quarter ended March 31, 2011. The first quarter of 2012 included the benefit of $736,000 in net gains on sales of other real estate owned compared to only $2,000 in net gains for the quarter ended March 31, 2011.

Total assets as of March 31, 2012 were $437.6 million compared to $427.5 million as of December 31, 2011; an increase of 2.4%. Loans, excluding loans held for sale, increased to $323.4 million, up 1.1% from $319.7 million as of December 31, 2011. Deposits during the same period increased3.7% to $327.8 million, while other borrowings decreased 3.5% to $64.5 million.

The Company’s ratio of nonperforming assets to total assets was 6.71% as of March 31, 2012, compared to 6.37% as of March 31, 2011. The allowance for loan losses as a percentage of loans was 2.96% as of March 31, 2012, compared to 2.66% as of March 31, 2011. This increase is directionally consistent with the level of nonperforming problem loans. The allowance for loan losses as a percentage of total nonperforming loans totaled 43.13% as of March 31, 2012, compared to 42.58% as of March 31, 2011.

The subsidiary bank’s capital position as of March 31, 2012 remains substantially in excess of regulatory well-capitalized requirements, with tier 1 capital to average assets of 9.41%. “We continue to be encouraged by the future direction of our Company given our capital strength and improvement in core operations,” concluded Pearson.

About Southcoast Financial Corporation

Southcoast Financial Corporation, headquartered in Mt. Pleasant, South Carolina, is the holding company of Southcoast Community Bank. The Bank, which opened for business July 20, 1998, is a state chartered commercial bank operating from its main office at 530 Johnnie Dodds Boulevard in Mt. Pleasant, South Carolina and nine branches in the Charleston, South Carolina area. Trading in Southcoast Financial Corporation’s common stock is traded on the NASDAQ Global Market under the symbol SOCB.

CONTACT: William C. Heslop, Senior Vice President and
         Chief Financial Officer, (843) 216-3019

SEFE, Inc. (SEFE): SEFE Highlights Third Patent

SEFE, Inc. (OTCBB: SEFE.OB) (“SEFE”) (“The Company”), a technology- and solutions-driven sustainability company, focused today on the issuance of U.S. Patent #8,102,082 issued from the U.S. Patent and Trademark Office (USPTO) for an “Atmospheric Static Electricity Collector.” The patent was filed by the Company in September 2007. The Company believes this issuance stands as another milestone in SEFE’s mission to establish itself as a cornerstone of the atmospheric technology community.

Michael Hurowitz, SEFE Director of Engineering, said, “We have been able to develop a number of inventions around the Harmony III project that provide value in our industry and other industries as well. We will continue to strengthen our patent portfolio in order to remain competitive in our industry.”

“We were hopeful that we would get this patent awarded as an indication that the USPTO might recognize SEFE’s first position in atmospheric technology,” said Don Johnston, CEO of SEFE. “Our focus remains on the science and development of sustainable products to make ‘what-if’ a reality. These new issuances continue our drive to enhance shareholder value, with a focus on doing so responsibly, profitably, and sustainably. The new patent should make a significant contribution to the overall valuation of our portfolio.”

For more information visit www.SEFElectric.com.

About SEFE, Inc.

SEFE focuses on pushing the boundaries of what’s possible, embracing innovation and employing the cutting-edge to solve problems, and offering sustainable solutions to a world hungry for invention, direction and leadership. SEFE is technology- and solutions-driven, focusing on developing inventions that provide a real-world impact and true profitability. So, success is measured by both a sustainable return on investment, as well as a project’s sustainability from an environmental perspective.

For more information, visit www.SEFElectric.com.

Forward-Looking Statements

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Trunkbow (TBOW) and China Unicom to Bring Mobile Payments to Sichuan Province

BEIJING, April 11, 2012 /PRNewswire-Asia/ — Trunkbow International Holdings Limited (NASDAQ: TBOW) (“Trunkbow” or the “Company”), a leading provider of Mobile Payment Solutions (“MPS”) and Mobile Value Added Solutions (“MVAS”) in China, today announced that it has extended its cooperation with China Unicom through the deployment of a new terminal-based MPS platform in Sichuan Province. Implementation of the platform began in the first quarter of 2012, and services are expected to launch in the second or third quarter.

“This partnership is another important step toward our goal of further extending Trunkbow’s leadership position in the emerging Chinese MPS market, and this expanded footprint should help support our ongoing merchant acquisition efforts,” said Mr. Qiang Li, CEO of Trunkbow. “We believe that partnering with enterprises and institutions to use MPS as an authentication tool is an excellent complement to the transaction processing applications with physical merchants at the point-of-sale. Our primary goal for 2012 is to drive adoption of MPS among merchants and consumers, and we believe that as businesses and academic institutions increasingly enable the use of MPS-based mobile handsets as an electronic identification tool, it will encourage end-users to further simplify their lives by using phones as a method of payment as well. We have a number of exciting projects planned that will significantly enhance the value proposition of MPS for merchants, consumers and enterprises through increased functionality and an expanded feature set, significantly increasing the range of end markets that can benefit from our technology solutions.”

Under the agreement, Trunkbow will receive recurring revenue payments based on a percentage of monthly subscriber fees and transactions processed using the MPS platform. During the first phase of deployment, Trunkbow and China Unicom will jointly market this MPS technology to corporations, academic institutions and other organizations as a SAAS and enterprise automation tool including authentication and internal payment functionalities. The companies plan to expand this marketing effort to include brick-and-mortar retail locations for point-of-sale payment applications following the initial ramp of enterprise installations.

This platform will allow China Unicom’s 5.5 million subscribers in Sichuan province to make purchases at retail locations using their mobile phones at the point-of-sale, and will function as a convenient, secure electronic identification card for students and employees at schools and other locations using the technology.

About Trunkbow

Trunkbow International Holdings (NASDAQ: TBOW) is a leading provider of Mobile Payment Solutions (“MPS”) and Mobile Value Added Solutions (“MVAS”) in PRC. Trunkbow’s solutions enable the telecom operators to offer their subscribers access to unique mobile applications, innovative tools, value-added services that create a superior mobile experience, and as a result generate higher average revenue per user and reduce subscriber churn. Since its inception in 2001, Trunkbow has established a proven track record of innovation, and has developed a significant market presence in both the Mobile Value Added and Mobile Payment solutions markets. Trunkbow supplies its mobile payment solutions to all three Chinese mobile telecom operators, as well as re-sellers, in several provinces of China. For more information, please visit www.trunkbow.com.

Safe Harbor Statement

This press release contains forward-looking statements that reflect the Company’s current expectations and views of future events that involve known and unknown risks, uncertainties and other factors that may cause its actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.  Such forward looking statements involve known and unknown risks and uncertainties, including but not limited to uncertainties relating to the Company’s relationship with China’s major telecom carriers and its resellers, competition from domestic and international companies, changes in technology, contributions from revenue sharing plans and general economic conditions. The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs.  You should understand that the Company’s actual future results may be materially different from and worse than what the Company expects. Information regarding these risks, uncertainties and other factors is included in the Company’s annual report on Form 10-K and other filings with the SEC.

Contact Information:

PURE Bioscience Introduces the PURE Complete Cleaning, Sanitizing and Disinfecting System

URE Bioscience, Inc. (NASDAQ: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported the launch of the PURE Complete Cleaning, Sanitizing and Disinfecting System. The PURE Complete System product line includes PURE Hard Surface disinfectant and food contact surface sanitizer, PURE Multi-Purpose Cleaner Concentrate and PURE Floor Cleaner Concentrate.

James McClenahan, Vice President of Sales for PURE Bioscience, stated, “With the addition of our PURE Multi-Purpose Cleaner Concentrate, we are pleased to now offer a comprehensive, cost effective and user-friendly product line to end-users, janitorial service providers and the distributors that supply them. The PURE Complete System strengthens infection control and sustainability programs for a wide range of environments, including hospitals, food processing facilities, restaurants, hospitality, schools, institutions, public facilities, transportation and businesses.

“Feedback from early marketing efforts is positive. Using a premium disinfectant as a cleaner is not the most cost effective way to clean, and we now can meet the specific needs of our customers by offering distinct product solutions priced competitively as a complete system,” continued McClenahan. “This budget-focused approach is opening doors for PURE Hard Surface as a next generation disinfectant/sanitizer product.”

About PURE Floor Cleaner and Multi-Purpose Concentrates

PURE’s non-toxic, environmentally responsible cleaning products are protected by SDC, a natural, non-toxic antimicrobial. SDC ensures the quality and safety of PURE Floor Cleaner and PURE Multi-Purpose Cleaner without human or environmental exposure to toxic chemical preservatives. PURE Floor Cleaner and PURE Multi-Purpose cleaner are non-flammable and contain no EDTA, phosphates, ammonia or bleach as well as no VOCs or NPEs. PURE Floor Cleaner and PURE Multi-Purpose Cleaner provide professional strength cleaning in a concentrate formula that yields a 1:128 use dilution that is safe for use on all resilient surfaces. The active ingredients in the cleaner products meet the US EPA’s DfE (Design for the Environment) Criteria for Safer Chemical Ingredients.

About PURE Hard Surface

U.S. EPA-registered PURE Hard Surface disinfectant and food contact surface sanitizer provides an unparalleled combination of high efficacy and low toxicity with 30-second bacterial and viral kill times and 24-hour residual protection. SDC-based PURE Hard Surface completely kills resistant pathogens like MRSA and Carbapenem-resistant Klebsiella pneumoniae (NDM-1) and also effectively eliminates dangerous fungi and viruses including HIV, Hepatitis B, Hepatitis C, Norovirus, Influenza A, Avian Influenza and H1N1 as well as hazardous food pathogens such as E. coli, Salmonella and Campylobacter. PURE Hard Surface delivers powerful broad-spectrum efficacy while remaining classified as least-toxic (Category IV) by the US EPA, and its active ingredient, SDC, has been determined Generally Recognized as Safe (GRAS) for use as a biocide on food processing equipment, machinery and utensils.

About PURE Bioscience, Inc.

PURE Bioscience, Inc. develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE’s proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today’s global trend toward industry and consumer use of “green” products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver, which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.

This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s cash position and liquidity requirements, the Company’s failure to implement or otherwise achieve the benefits of its strategic initiatives, acceptance of the Company’s current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50234632&lang=en

NeurogesX (NGSX) Provides Update on NGX-1998 Clinical Program

SAN MATEO, Calif., April 11, 2012 (GLOBE NEWSWIRE) — NeurogesX, Inc. (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s request for an End-of-Phase 2 meeting to discuss the continued clinical investigation of NGX-1998 as a treatment for certain neuropathic pain conditions including, specifically, the Company’s plans for entering NGX-1998 into Phase 3 development. The Company anticipates that the End-of-Phase 2 meeting will occur in the third quarter of 2012.

NGX-1998, NeurogesX’ most advanced product candidate, is a topically applied liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. The Company believes that the clinical data obtained to date should support moving to a Phase 3 clinical development program, which it believes can be initiated by the end of 2012.

The Phase 2 study that NeurogesX completed at the end of 2011 was a 12-week, multicenter, randomized, double-blinded, placebo-controlled clinical trial. Its protocol-specified objectives were met, including the primary endpoint of a percentage change from baseline as compared to placebo in a patient-reported numeric pain rating scale (NPRS) score during weeks two through eight. A total of 183 patients were treated in the Phase 2 study. Patients were randomized into one of three groups: NGX-1998 capsaicin 10% solution, NGX-1998 capsaicin 20% solution or placebo, according to an unequal allocation scheme of 2:2:1.  NGX-1998 exhibited a dose response. Although no topical anesthetic was used during the second stage of the study, the patients were able to tolerate the treatment procedure. No patients discontinued the study due to adverse events, and the incidence of adverse events and serious adverse events in patients treated with NGX-1998 were similar to the placebo-treated group.

About NeurogesX, Inc.

NeurogesX, Inc. (Nasdaq:NGSX) is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies to address unmet medical needs and improve patients’ quality of life.

The Company’s lead product, Qutenza^®, is currently approved in the United States and the European Union. Qutenza^® is now available in the United States for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In Europe, Qutenza^® is being marketed by Astellas Pharma Europe Ltd. (Astellas), the European affiliate of Tokyo-based Astellas Pharma Inc., for the treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain.

The Company’s most advanced product candidate, NGX-1998, is a topically applied liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 clinical trials and one Phase 2 clinical trial in PHN patients, and the Company believes that NGX-1998 is ready to enter Phase 3 development.

The Company’s early-stage pipeline includes pre-clinical compounds which include a number of prodrugs of acetaminophen. The Company has evaluated certain of these compounds in vitro and in vivo.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the Act).  NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act.  Examples of such statements include but are not limited to statements regarding: the sufficiency of currently held data to support moving NGX-1998 development into Phase 3, the potential entry of NGX-1998 into Phase 3 development by the end of 2012; and the timing of the End-of-Phase 2 meeting with the FDA.  Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: NGX-1998 may fail to demonstrate sufficient safety or efficacy in clinical trials to support further development or potential marketing approval; potential delays of the End-of-Phase 2 meeting with the FDA; difficulties or delays in the initiation of clinical trials for NGX-1998; Qutenza, NGX-1998 and NeurogesX’ other product candidates may have unexpected adverse side effects; NeurogesX may have insufficient resources to pursue clinical development of NGX-1998; and difficulties or delays in NeurogesX’ efforts to engage in strategic relationships with respect to development or commercialization of Qutenza or NGX-1998.  For further information regarding these and other risks related to NeurogesX’ business, investors should consult NeurogesX’ filings with the Securities and Exchange Commission.

CONTACT: NeurogesX, Inc.
         Stephen Ghiglieri
         Executive Vice President, COO and CFO
         (650) 358-3310
         sghiglieri@neurogesx.com

Satcon (SATC) Provides Business Update for First Quarter 2012

Satcon Technology Corporation® (NASDAQ CM:SATC), a leading provider of utility scale power conversion solutions for the renewable energy market, today provided a business update and certain preliminary unaudited financial results for its first quarter ended March 31, 2012.

Based on preliminary financial data and subject to the final closing of the company’s books, Satcon expects first-quarter 2012 revenue will be between $22 million and $25 million, in line with its previously announced guidance of $22 million to $28 million. Bookings for the first quarter were approximately $45 million, an increase of approximately 130% from the fourth quarter of 2011 and 27% from the first quarter of 2011. In addition, the quarter was the company’s most successful bookings period in four quarters, with a book-to-bill ratio of 1.9:1.

“The strategic measures that Satcon has implemented throughout the quarter continue to position the company for both improved financial performance and increased market share in the world’s highest growth solar markets,” said Steve Rhoades, Satcon’s President and Chief Executive Officer. “Bookings in the first quarter of 2012 demonstrate the strong demand for our industry leading solutions. We made significant progress in improving our balance sheet, reducing our working capital while paying down a significant portion of our short- and long-term debt. These actions have strengthened our cash flow position and have provided sufficient liquidity to meet our obligations and pursue our long-term growth strategy. The commercial success we have achieved in the quarter, along with the significant progress the company has made since the implementation of our strategic organizational alignment over the past six months, lay the foundation for profitable growth going forward.”

About Satcon

Satcon Technology Corporation is a leading provider of utility-grade power conversion solutions for the renewable energy market, enabling the industry’s most advanced, reliable and proven clean energy alternatives. For more than ten years, Satcon has designed and delivered advanced power conversion products that enable large-scale producers of renewable energy to convert the clean energy they produce into grid-connected efficient and reliable power. To learn more about Satcon, please visit http://www.Satcon.com.

Safe Harbor

Statements made in this document that are not historical facts or which apply prospectively, including those relating to preliminary Q1 2012 financial results, are forward-looking statements that involve risks and uncertainties. These forward-looking statements are identified by the use of terms and phrases such as “will,” “intends,” “believes,” “expects,” “plans,” “anticipates” and similar expressions. Investors should not rely on forward looking statements because they are subject to a variety of risks and uncertainties and other factors that could cause actual results to differ materially from the company’s expectation. Additional information concerning risk factors is contained from time to time in the company’s SEC filings, including its Annual Report on Form 10-K and other periodic reports filed with the SEC. Forward-looking statements contained in this press release speak only as of the date of this release. Subsequent events or circumstances occurring after such date may render these statements incomplete or out of date. The company expressly disclaims any obligation to update the information contained in this release.

Video Display Corp. (VIDE) Subsidiary Forms New Division

ATLANTA, April 9, 2012 (GLOBE NEWSWIRE) — Video Display Corporation (Nasdaq:VIDE) announces that its Aydin Displays, Inc. subsidiary, a worldwide leader in providing ruggedized products for the industrial and military markets, has formed a new division, Aydin CyberSecurity, located in Palm Bay, Florida. The company’s announcement reflects the continuing effort by Aydin and Video Display Corporation to further increase the company’s products and services as it drives for greater growth and diversity.

Aydin CyberSecurity specializes in advanced TEMPEST technology and products and custom engineering solutions to include extreme environmental performance and survivability technologies (MIL-STD-810 and 00-160) in support of military forces, intelligence agencies, prime contractors and niche commercial sectors worldwide.

Through succession, Aydin CyberSecurity is heir to 40 years of specialty TEMPEST technology. TEMPEST is a classified application for limiting electromagnetic radiation emissions from electronic equipment in order to prevent its unauthorized disclosure. The Company serves two primary markets – first, the Military and Intelligence communities. Secondary markets include niche commercial first responders. The emphasis is on systems that require any combination of high-reliability, redundant architectures and stringent security requirements. The company’s longevity and reputation further bolsters the confidence customers can place in Aydin CyberSecurity as the best-value, low-risk source for their program objectives.

The company supplies a variety of projects and solutions that span multiple disciplines, applications, and industries as an original equipment manufacturer (OEM), a Value Added Reseller (VAR), and a prime or sub-contractor. The organization is adept at managing large scale, globally dispersed IDIQ contracts alone or with multiple partners and subcontractors.

Aydin CyberSecurity’s Palm Bay, Florida operations are located in a 25,000 sq. ft., restricted card facility and is ISO 900 I :2000 certified. The facility is outfitted with a full range of manufacturing, testing equipment, and three NSA-endorsed test chambers. The facility is approved under the U.S. Government’s Certified TEMPEST Products Program1 and maintains a DoD Approved Facility Clearance.

Aydin Displays is a leading provider in display manufacturing technology, servicing the industrial, military and air traffic control industries. Aydin offers a variety of industrial displays, rugged Military/COTS Flat Panel Displays, Military Panel PC Workstations, and Air Traffic Control Displays ranging in size from 6.4″ to 57″ now with the added capability of TEMPEST and TEMPEST certification. For more information, visit Aydin’s web site at www.aydindisplays.com.

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition, from time to time, Video Display Corporation or its representatives have made or may make forward-looking statements, orally or in writing. Such forward-looking statements may be included in, but are not limited to, various filings made by the Company with the Securities and Exchange Commission, press releases or oral statements made with the approval of an authorized executive officer of the Company. Actual results could differ materially from those projected or suggested in any forward-looking statements as a result of a wide variety of factors and conditions, including items discussed in the Company’s Form 10-K for the year ended February 28, 2011, filed with the Securities and Exchange Commission. The Company undertakes no duty to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.

Lihua on Track (LIWA) to Launch Production on New Smelters in April

DANYANG, China, April 9, 2012 /PRNewswire-Asia/ — Lihua International, Inc. (NASDAQ: LIWA) (“Lihua” or the “Company”), a leading Chinese developer, designer, and manufacturer of low cost, high quality alternatives to pure copper products, including refined copper products and superfine and magnet wire, as well as copper clad aluminum (“CCA”) wire, today announced that it is on track to commence production of copper anode on its two new smelters by the end of April. The construction team is currently completing the connection of the recycling system to the smelters and the dedicated power grid. Each of these smelters will add 25,000-30,000 tons of copper anode capacity on an annualized basis, giving Lihua a total of 85,000-95,000 tons of copper anode capacity per year and a total of 135,000 – 145,000 tons of refined copper production capacity per year.

“Despite the recent weakness in Lihua’s share price, there have been no developments within the Company that would warrant this level of volatility. On the contrary, our business has never been stronger,” said Mr. Jianhua Zhu, Lihua’s Chairman and Chief Executive Officer. “Demand from our primary copper anode customers continues to grow, and the volume demand from our largest customer alone already exceeds our post-expansion production capacity. Several weeks ago, we reported record results for 2011 and guided for year-over-year growth of more than 20% in both gross profit and non-GAAP net income in 2012. We remain confident in Lihua’s growth prospects and the fundamental strength of our business. With a number of catalysts that we expect will begin having a positive effect on our business in the near future, as well as continued support from our loyal investors, we believe that our Company’s valuation can become more aligned with and better reflect the strength of our business.”

Lihua carefully monitors its stock’s trading patterns. The Company is currently reviewing recent unusual trading activity and plans to report any suspicious activity to the U.S. Securities and Exchange Commission, as appropriate.

Lihua reiterated its financial guidance for full-year 2012 gross profit to be between $93 million and $96 million, and non-GAAP net income between $61 million and $64 million, representing year-over-year growth of 23-27% and 22-28%, respectively. The Company expects that 2012 growth will be largely the result of continued strong demand in China for recycled copper and copper alternative products in the overall copper consumption market including the household appliance, consumer white goods and infrastructure markets, as well as the increase in production capacity. In addition, the Company will distribute its second special dividend of $0.03 per share on April 13, 2012 to shareholders of record as of March 31, 2012.

About Lihua International, Inc.

Lihua, through its two wholly owned subsidiaries, Lihua Electron and Lihua Copper, is a leading value-added manufacturer of copper replacement products for China’s rapidly growing copper wire and copper replacement product market. Lihua is one of the first vertically integrated companies in China to develop, design and manufacture lower cost, high quality alternatives to pure copper magnet wire and pure copper alternative products. Lihua’s products include CCA and refined copper products. Current product offerings include CCA and pure copper wire, copper rod and copper anode. Except for CCA wire, all other products are produced from recycled scrap copper. Lihua’s products are sold in China either directly to manufacturers or through distributors in the wire and cable industries and manufacturers in a wide variety of industries including the consumer electronics, white goods, automotive, utility, telecommunications and specialty cable industries. Lihua’s corporate and manufacturing headquarters are located in the heart of China’s copper industry in Danyang, Jiangsu Province. For more information, visit: http://www.lihuaintl.com.

To be added to the Company’s email distribution for future news releases, please send your request to lihua@tpg-ir.com.

Safe Harbor Statement

This press release contains certain statements that may be deemed to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, that address activities, events or developments that the Company expects, projects, believes or anticipates will or may occur in the future, including, without limitation, statements about its business or growth strategy, general industry conditions including availability of copper or recycled scrap copper, future operating results of the Company, capital expenditures, expansion and growth opportunities, bank borrowings, financing activities and other such matters, are forward-looking statements. Although the Company believes that its expectations stated in this press release are based on reasonable assumptions, actual results may differ from those projected in the forward-looking statements.

Please note that information in this press release reflects management views as of the date of issuance.

Contact:

The Piacente Group, Inc.
Investor Relations
Brandi Floberg or Lee Roth
(212) 481-2050
lihua@tpg-ir.com

SOURCE Lihua International, Inc.

China BAK (CBAK) Announces Additional Contract to Supply High-Power Batteries to Chery Automobile

SHENZHEN, China, April 9, 2012 /PRNewswire-Asia/ — China BAK Battery, Inc. (“China BAK”, the “Company”, or “we”) (Nasdaq: CBAK), a leading global manufacturer of lithium-based battery cells, today announced that on April 9, 2012, the Company entered into a new contract to supply high-power batteries to Chery Automobile Co., Ltd. (“Chery”).

Under the contract, China BAK will deliver 1,000 lithium-ion high-power battery units in 2012 to power Chery’s Ruilin M1 electric cars. The new contract is in addition to the Company’s previously-announced contract with Chery, entered into in February 2012, to supply 100 high-power battery units to Chery, which are on schedule to be delivered by June 2012. The Ruilin M1 is one of the five electric vehicle models that have been approved for government use since early this year.

Additionally, the Company announced that it will hold a joint press conference with Chery in mid-April in Tianjin. At the press conference, Chery and China BAK plan to announce a long-term cooperation program in the electric vehicles industry and invite an interactive discussion with the attendees.

“We believe that this additional order from Chery, and their anticipated further orders and cooperation, further underline our ability to deliver high-quality battery products and lead the development of China’s emerging electric vehicle battery market. Likewise, we continue to expect additional orders from other domestic customers for our lithium-ion high-power batteries to power electric vehicles in China in 2012,” commented Mr. Xiangqian Li, CEO of China BAK.

About China BAK Battery, Inc.

China BAK Battery, Inc. (NASDAQ: CBAK) is a leading global manufacturer of lithium-based battery cells. The Company produces battery cells that are the principal component of rechargeable batteries commonly used in cellular phones, smartphones, notebook computers, e-bikes, electric vehicles, power tools, uninterruptible power supplies, and portable consumer electronics such as portable media players, portable gaming devices, personal digital assistants, or PDAs, camcorders, digital cameras, and Bluetooth headsets. China BAK Battery, Inc.’s production facilities, located in Shenzhen and Tianjin, PRC, cover over three million square feet. For more information regarding China BAK Battery, Inc., please visit http://www.bak.com.cn.

Safe Harbor Statement

This press release contains forward-looking statements, which are subject to change. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All “forward-looking statements” relating to the business of China BAK Battery, Inc. and its subsidiary companies, which can be identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions, involve known and unknown risks and uncertainties which could cause actual results to differ. These factors include but are not limited to: the ability of the Company to meet its contract obligations; the uncertain market for the Company’s high-power lithium and other battery cells; business, macroeconomic, technological, regulatory, or other factors affecting the profitability of battery cells designed for electric vehicles; risks related to China BAK’s business and risks related to operating in China. Please refer to China BAK’s Annual Report on Form 10-K for the fiscal year ended September 30, 2011, as well as China BAK’s Quarterly Reports on Form 10-Q that have been filed since the date of such annual report, for specific details on risk factors. Given these risks and uncertainties, you are cautioned not to place undue reliance on forward-looking statements. China BAK’s actual results could differ materially from those contained in the forward-looking statements. China BAK undertakes no obligation to revise or update its forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

SEFE Inc. (SEFE) Receives Patent for Dynamic Electrical Converter System

SEFE, Inc. (OTCBB: SEFE.OB) (“SEFE”) (“The Company”), a technology and solutions-driven sustainability company, announced today that it is the recipient of U.S. Patent #8,102,078 issued by the United States Patent and Trademark Office (USPTO) for a “Dynamic Electrical Converter System.” The patent was filed on September 4, 2008. The Company believes that this issuance further establishes SEFE as the owner of foundational atmospheric energy technology.

In layman’s terms, the dynamic electrical converter system receives the variable voltage collected by the Harmony III airborne unit from static electricity in the atmosphere, and converts it into a usable electrical configuration. The system includes a monitor to check the incoming voltage as well as multiple converters, each of which can accept a unique range of voltages and create the desired electrical output.

“We have worked diligently, with the help of our engineering and scientific teams, to develop sound intellectual property around our Harmony III product,” said Michael Hurowitz, SEFE Director of Engineering. “The issuance by the USPTO validates the unique nature of our company and the approaches we are taking to solve real-world energy problems. We believe additional coverage of the space will be awarded to SEFE in the near term, and will continue to add to the inventions.”

“This issuance provides further validation of our company’s core technology and increases our patent claims in key new areas for our business,” said Don Johnston, Chief Executive Officer of SEFE, Inc. “The USPTO again recognizes SEFE’s first position and our contribution to the field of atmospheric technology. This issuance is a long-awaited milestone in the development of our foundational intellectual property portfolio, and a victory for our company and its shareholders. The new patent should make a significant contribution to the overall valuation of our portfolio.”

About SEFE, Inc.

SEFE focuses on pushing the boundaries of what’s possible, embracing innovation and employing the cutting-edge to solve problems, and offering sustainable solutions to a world hungry for invention, direction and leadership. SEFE is technology- and solutions-driven, focusing on developing inventions that provide a real-world impact and true profitability. So, success is measured by both a sustainable return on investment, as well as a project’s sustainability from an environmental perspective.

For more information, visit www.SEFElectric.com.

Forward-Looking Statements

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Carrollton Bancorp (CRRB) and Jefferson Bancorp, Inc. Agree to Merger

Jefferson Bancorp, Inc., parent company for Bay Bank, FSB and Carrollton Bancorp (Nasdaq: CRRB), parent company for Carrollton Bank, today announced the execution of a definitive agreement for merger of Jefferson Bancorp, Inc (“Jefferson”) and Carrollton Bancorp (“Carrollton”). The subsidiary banks, Bay Bank, FSB and Carrollton Bank will also merge, with Bay Bank, FSB being the surviving entity. The transaction is currently valued at approximately $25 million in stock and cash, representing $15.4 million in consideration to Carrollton shareholders and repayment of $9.1 million in TARP funding to the US Treasury. The transaction will combine the strengths of the two organizations in the Maryland market with a combined 12 bank branches in the Baltimore/Washington market.

“The Board is very excited about this transaction. It represents the execution of our stated strategy to be opportunistic in our growth through mergers with like minded Maryland community banks,” said Kevin Byrnes, Chairman of Bay Bank. “We believe that our access to capital when coupled with our highly experienced management team will allow us to grow to the scale necessary to meet the needs of our customers on a full service basis.”

Carrollton will be the surviving holding company in the merger and the transaction is structured as a tax-free reorganization. In exchange for 100% of the outstanding shares of Jefferson, Financial Services Partners Fund I (“FSPF”) and the other shareholders of Jefferson, after an $11 million incremental investment by FSPF in Jefferson prior to the merger, will receive newly issued shares of Carrollton common stock representing approximately 85.92% of the total outstanding shares of Carrollton as of the closing of the merger, assuming the current Carrollton shareholders elect to exchange for cash fully 50% of the current outstanding shares of common stock of Carrollton. This represents a fixed exchange ratio of 2.2217 Carrollton shares for each Jefferson share and values Carrollton shares at $6.20 per share. In connection with the merger, the current Carrollton shareholders will be entitled to elect to exchange for $6.20 per share up to 50% of the currently outstanding shares of Carrollton common stock in the aggregate.

“We have been very pleased with the performance of our initial investment in Jefferson and are delighted to be contributing additional equity to facilitate the formation of a strengthened franchise in the Baltimore-Washington market with scale, talent and resources required to provide excellence in community banking services in the future,” said Joseph J. Thomas, Managing Director of Hovde Private Equity Advisors LLC and Chairman of Jefferson Bancorp, Inc.

On a pro forma consolidated basis, the new Carrollton will have approximately $472.3 million in total assets, $382.8 million in gross loans, and $412.9 million in total deposits, after purchase accounting adjustments. The combined bank will have tangible common equity in excess of 10% and reduced levels of non-performing assets relative to capital as compared to Carrollton on a stand-alone basis. Furthermore, the revenue synergies and cost savings in the transaction are expected to demonstrably improve profitability and return on capital as compared to Carrollton on a stand-alone basis. The new Carrollton Board of Directors will consist of six existing Jefferson directors and three directors from the legacy Carrollton Board.

“Carrollton Bank has done a wonderful job of serving the Baltimore market for over 100 years with a strong commitment to the community. Carrollton has a solid retail branch network, a successful mortgage operation, and an innovative mix of fee-based products. We look forward to combining the strengths of the two organizations to better serve the market with high quality people and a superior customer service experience,” said Kevin B. Cashen, President and Chief Executive Officer of Jefferson, who will serve as President and Chief Executive Officer of Carrollton after the merger. “We are very happy that, with this merger, we will be well positioned to become the bank of choice for those consumers and businesses looking for a strong, local bank with deep roots in the community.”

Carrollton Bank’s President and CEO, Robert Altieri, will join the management team of Bay Bank as an Executive Vice President, managing several of the bank’s core businesses. Mr. Altieri will also be an integral part of the efforts to effectively integrate the two banks. “Bob has been a long-term banker in this market and has a tremendous reputation. We are very excited to have him with us on the executive management team to help grow our franchise and expand our business lines,” said Cashen.

“Bay Bank has made a strong push into the Maryland banking market over the past two years and we are very excited to join forces to further expand our market share. We believe that each organization brings unique strengths to the combined bank and that we will be well positioned to become a dominant community bank in the market,” said Robert Altieri.

The transaction, which has been approved by both Carrollton’s and Jefferson’s boards of directors, is expected to close in the third quarter of 2012. The transaction is subject to certain customary conditions, including the approval by Carrollton’s shareholders and regulatory approvals.

Monocacy Financial Advisors, LLC acted as financial advisor to Carrollton and K&L Gates is acting as Carrollton’s legal counsel. Arnold & Porter LLP is acting as legal counsel to Jefferson.

About Jefferson Bancorp, Inc. /Bay Bank, FSB

Jefferson Bancorp, Inc was formed in July 2010 to acquire certain assets and assume certain liabilities of Bay National Bank from the Federal Deposit Insurance Corporation. Substantially all of the Jefferson Bancorp’s outstanding common shares are owned by Financial Services Partners Fund I LLC (“FSPF”). FSPF is a Delaware limited liability company established on July 1, 2005, to pursue equity investments in banks, thrifts, insurance and specialty finance institutions. Jefferson Bancorp, Inc. is a savings & loan holding company for Bay Bank, FSB. Bay Bank, FSB is headquartered in Lutherville, Maryland, and is focused on providing superior customer service to small and medium-sized businesses, their owners and professionals located throughout the region. Its core products are commercial loans, real estate loans, commercial and consumer deposit services, cash management services and consumer loans. As of December 31, 2011, Bay Bank had total assets of approximately $130 million and two branch locations. Please visit Bay Bank’s website at www.baybankmd.com for additional information.

About Carrollton Bancorp/Carrollton Bank

Carrollton Bank is a wholly-owned subsidiary of Carrollton Bancorp, a publicly traded bank holding company (NASDAQ: CRRB) headquartered in Columbia, Maryland. Carrollton Bank has been committed to providing outstanding financial service to the central Maryland region for more than 100 years. Carrollton Bank provides a wide range of financial services for personal and business banking customers, including a variety of checking accounts, competitive rates on certificates of deposit and savings accounts, commercial lending, free nationwide ATMs with the MoneyPass® symbol, mortgages, investment services* and 24-hour internet and telephone banking. As of December 31, 2011, Carrollton Bank had approximately $365 million in total assets and ten (10) branch locations in the region. Please visit Carrollton Bank’s website at www.carrolltonbank.com for additional information.

Additional Information about the Merger and Where to Find It

In connection with the proposed merger transaction, Carrollton Bancorp will file with the Securities and Exchange Commission a Proxy Statement as well as other relevant documents concerning the proposed transaction. Shareholders are urged to read the Proxy Statement regarding the merger when it becomes available and any other relevant documents filed with the SEC, as well as any amendments or supplements to those documents, because they will contain important information.

A free copy of the Proxy Statement, as well as other filings containing information about Carrollton Bancorp may be obtained at the SEC’s website at http://www.sec.gov. You will also be able to obtain these documents, free of charge, from Carrollton Bancorp at www.carrolltonbank.com under the tab “Investor Relations”.

Jefferson Bancorp and Carrollton Bancorp and certain of their directors and executive officers may be deemed to be participants in the solicitation of proxies from the shareholders of Carrollton Bancorp in connection with the proposed merger. Information about the directors and executive officers of Carrollton Bancorp is set forth on the Carrollton Bancorp website in the “Investor Relations” tab. Information about the directors and executive officers of Jefferson Bancorp/Bay Bank is set forth on the Bay Bank website in the “About Bay Bank” tab. Additional information regarding the interests of those participants and other persons who may be deemed participants in the transaction may be obtained by reading the Proxy Statement regarding the proposed merger when it becomes available. Free copies of this document may be obtained as described in the preceding paragraph.

* Investment products offered through Carrollton Financial Services, Inc. are not deposits or other obligations of Carrollton Bank or any affiliate; are not insured by the Federal Deposit Insurance Corporation (FDIC) or any other agency of the United States Government, Carrollton Bancorp or any affiliate; and in case of a product that is subject to investment risk, there is possible loss of value.

Forward-Looking Statement:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning Carrollton and Jefferson and the financial condition and projected expenses of Carrollton, Jefferson and the combined company. These forward-looking statements about future expectations, plans and prospects of Carrollton, Jefferson and the combined company involve significant risks, uncertainties and assumptions, including risks that can be found in the “Risk Factors” section of the Carrollton Annual Report on Form 10-K on file with the Securities and Exchange Commission and the other reports that Carrollton periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Carrollton contemplated by these forward-looking statements. These forward looking statements reflect management’s current views and Carrollton does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.

New Frontier Media’s (NOOF) Special Committee Retains Financial Advisor to Assist in Evaluating Strategic Alternatives

BOULDER, Colo., April 3, 2012 /PRNewswire/ — New Frontier Media, Inc. (NasdaqGS: NOOF), a leading provider of transactional television services and distributor of general motion picture entertainment, today announced that the Special Committee of the Board of Directors of New Frontier Media has retained Avondale Partners, LLC, a nationally recognized full service investment banking firm, as its financial advisor to examine and consider a broad range of strategic alternatives. The strategic review will evaluate the Company’s current long-term business plan against a broad range of alternatives that have the potential to maximize shareholder value. The process to review strategic alternatives will be overseen by the Special Committee of independent directors that, as previously announced, is also evaluating the recent unsolicited non-binding acquisition proposals that were recently received by New Frontier Media. The Special Committee is also being assisted by its legal advisor, Alston & Bird LLP. New Frontier Media is being advised by Holland & Hart LLP.

Alan L. Isaacman, Chairman of the Special Committee, stated that, “Our Board of Directors remains very enthusiastic about New Frontier Media’s future prospects and has made no decision to sell the Company. However, in keeping with our commitment to act in the best interests of all shareholders, we have decided to undergo a thorough review of strategic alternatives to determine the best opportunities for maximizing shareholder value at this time. Accordingly, while our financial advisor will assist us with reviewing and responding to the unsolicited acquisition proposals that we have received, as well as any other acquisition proposals that we may receive, the scope of our financial advisor’s assignment will be comprehensive and not limited to any specific vision for New Frontier Media’s future.”

The Special Committee, working with its financial and legal advisors, intends to proceed in a timely and orderly manner to consider a broad range of possible strategic alternatives for New Frontier Media and their implications, but has not set a definite schedule for the completion of its evaluation.

New Frontier Media cautions that there are no guarantees that the strategic alternative review process will result in a transaction or, if a transaction is approved by the New Frontier Media Board of Directors, whether the terms or timing of such a transaction will be approved by shareholders.

New Frontier Media currently does not intend to make any further public announcements regarding its Special Committee’s review of possible strategic alternatives until such time as the New Frontier Media Board of Directors approves a transaction or otherwise determines that further disclosure is appropriate.

About New Frontier Media, Inc.
New Frontier Media, Inc. is a provider of transactional television services and a distributor of general motion picture entertainment. Our Transactional TV segment distributes adult content to cable and satellite providers who then distribute the content to retail consumers via video-on-demand (VOD) and pay-per-view (PPV) technology. Programming originates from our state of the art digital broadcast infrastructure in Boulder, Colorado. We obtain our programming primarily by licensing content distribution rights from movie studios, and we distribute new and unique programming in order to provide consumers with an exceptional viewing experience.

Our Film Production segment is a distributor of mainstream and erotic films. The films are distributed to cable and satellite operators, premium movie channel providers and other content distributors. We act as a sales agent for mainstream films and produce erotic films. The segment also periodically provides contract film production services to major Hollywood studios.

We are headquartered in Boulder, Colorado, and our common stock is listed on the Nasdaq Global Select Market under the symbol “NOOF.” For more information about New Frontier Media, Inc., contact Grant Williams, Chief Financial Officer, at (303) 444-0900, extension 2185, and please visit our web site at www.noof.com.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “demonstrate,” “expect,” “estimate,” “anticipate,” “should” and “likely” and similar expressions identify forward-looking statements. In addition, statements that are not historical should also be considered forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. Forward-looking statements contained in this release may relate to, but are not limited to, statements regarding the review by New Frontier Media’s special committee of independent directors of potential strategic alternatives, the timing of such review, and the outcome of such review. Such forward-looking statements are based on current expectations that involve a number of known and unknown risks, uncertainties and other factors which may cause actual events to be materially different from those expressed or implied by such forward-looking statements. These factors include, but are not limited to, the risks detailed in New Frontier Media’s filings with the Securities and Exchange Commission, including its most recent filings on Form 10-K and Form 10-Q , or in information disclosed in public conference calls, the date and time of which are released beforehand. New Frontier Media is under no obligation to (and expressly disclaims any such obligation to) update any of the information in this press release if any forward-looking statement later turns out to be inaccurate whether as a result of new information, future events or otherwise.

Yongye International (YONG) Provides Update on Accounts Receivable Collection

BEIJING, April 3, 2012 /PRNewswire-Asia-FirstCall/ — Yongye International, Inc. (NASDAQ: YONG), (“Yongye” or the “Company”) a leading developer, manufacturer, and distributor of crop nutrient products in the People’s Republic of China (“PRC”), today provided an update on accounts receivable collection as of the quarter ended March 31, 2012.

During the first quarter of 2012 the Company collected $140 million of $154 million accounts receivable, net of allowance for doubtful accounts at the end of 2011. The Company has taken measures to increase its collection efforts and closely monitor its distributors’ financial status, and it expects to collect the remaining accounts receivable balance in the second quarter of 2012.

The Company’s regular payment terms allow distributors to pay the total purchase price within six months after the receipt of the Company’s products. Recent tightening of local credit markets has increased utilization of the Company’s full six month credit term by its distributors, which contributed to the Company’s account receivables at the end of 2011. The delay in payments from the distributors was not due to excessive inventories of unsold product held by such distributors, nor was it due to a decrease in demand for Yongye products among distributors and end customers.

Mr. Zishen Wu, Chairman and Chief Executive Officer of Yongye, stated, “We are pleased to provide a positive update on our accounts receivable collection. Yongye’s continued operating success is a testament to our leading products, innovative sales and marketing, and our strong and secure relationships with our distributors with whom we are very pleased to partner.”

About Yongye International, Inc.

Yongye International, Inc. is a leading crop nutrient company headquartered in Beijing, with its production facilities located in Hohhot, Inner Mongolia, China. Yongye’s principal product is a liquid crop nutrient, from which the Company derived substantially all of the sales in 2011. The Company also produces powder animal nutrient product which is mainly used for dairy cows. Both products are sold under the trade name “Shengmingsu,” which means “life essential” in Chinese. The Company’s patented formula utilizes fulvic acid as the primary compound base and is combined with various micro and macro nutrients that are essential for the health of the crops. The Company sells its products primarily to provincial level distributors, who sell to the end-users either directly or indirectly through county-level and village-level distributors. For more information, please visit the Company’s website at www.yongyeintl.com.

Safe Harbor Statement

This press release contains certain statements that may include “forward-looking statements.” All statements other than statements of historical fact included herein are “forward-looking statements.” These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including the risk factors discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on the SEC’s website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Contacts

Yongye International, Inc.
Ms. Kelly Wang
Finance Director – Capital Markets
Phone: +86-10-8231-9608
E-mail: ir@yongyeintl.com

Ms. Wendy Xuan
Business Associate
Phone: +86-10-8232-8866 x 8827
E-mail: ir@yongyeintl.com

FTI Consulting
Mr. John Capodanno (U.S. Contact)
Phone: +1-212-850-5705
E-mail: john.capodanno@fticonsulting.com

Ms. Mingxia Li (China Contact)
Phone: +86-10-8591-1060
E-mail: mingxia.li@fticonsulting.com

Marshall Edwards (MSHL) Announces Data from Clinical Trial of ME-143 Selected for Presentation at ASCO Annual Meeting

SAN DIEGO, April 3, 2012 /PRNewswire/ — Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that data from a Phase I clinical trial of the Company’s lead drug candidate ME-143 has been selected for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 1-5, 2012, in Chicago. An abstract of the presentation, entitled “ME-143, a novel inhibitor of tumor-specific NADH oxidase (tNOX): Results from a first-in-human phase I study,” will be available online at www.asco.org approximately two weeks before the Annual Meeting.

“This represents an exciting opportunity to present the data from our trial of ME-143 to oncology thought leaders from around the world,” said Robert Mass, M.D., Chief Medical Officer of Marshall Edwards. “These data will be instrumental as we prepare for the first of our randomized Phase II clinical trials later this year. We are grateful for the ongoing commitment of the clinical investigators, trial coordinators and especially the patients who participated in this study.”

Marshall Edwards recently completed enrollment of the fourth cohort in the Phase I clinical trial of ME-143. The dose-escalation trial is evaluating the safety and tolerability of ME-143 in patients with refractory solid tumors. In addition, the trial is designed to characterize the pharmacokinetic profile of intravenous ME-143 and describe any preliminary clinical anti-tumor activity observed. The multi-center trial is being conducted in collaboration with the Sarah Cannon Research Institute.

About Marshall Edwards

Marshall Edwards, Inc. (Nasdaq: MSHL) is a San Diego-based oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company’s lead drug candidates, ME-143 and ME-344, have been shown in laboratory studies to interact with specific enzyme targets resulting in inhibition of tumor cell metabolism, a function critical for cancer cell survival. Marshall Edwards initiated a Phase I clinical trial of intravenous ME-143 in patients with solid refractory tumors in September 2011 and plans to present safety and pharmacokinetic data from the trial at the American Society of Clinical Oncology Annual Meeting in June 2012. The Company submitted an Investigational New Drug application for ME-344 in March 2012 and plans to initiate a Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors immediately following approval by the FDA. For more information, please visit www.marshalledwardsinc.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management’s current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

GlobalWise (GWIV) Announces Channel Sales Partnership With ImageSoft

COLUMBUS, OH — (Marketwire) — 04/03/12 — GlobalWise Investments, Inc. (OTCBB: GWIV) (OTCQB: GWIV) (www.GlobalWiseInvestments.com) and its wholly owned subsidiary Intellinetics, Inc., a leading-edge technology company focused on the design, implementation and management of cloud-based Enterprise Content Management (“ECM”) systems in both the public and private sectors, today announce a Channel Sales Partnership contract has been executed with ImageSoft, Inc.

ImageSoft (www.imagesoftinc.com) provides innovative content management solutions that enable organizations to operate more efficiently and effectively. Founded in 1996, ImageSoft provides high-end ECM software products to serve state and county governments, insurance, healthcare, court systems and educational institutions. ImageSoft has ECM clients within the United States, Canada and Mexico.

“We are very pleased to announce the addition of the Intellivue™ ECM Solution to our technology offering,” said Scott Bade, ImageSoft President. “Intellivue will help us expand in several key markets where we already have a presence.” Since 2000 ImageSoft, Inc. has been a Platinum partner of one of Gartner Magic Quadrant’s top ECM companies. “Intellivue has focused on tight integration with key line-of-business applications, with an aggressive pricing strategy that fits a wide range of customers,” concluded Mr. Bade.

“By partnering with Intellinetics, ImageSoft now has an affordable, cloud-based ECM solution for the small-to-mid sized client,” stated William J. “BJ” Santiago, CEO of GlobalWise. “We expect this relationship will open many new doors for Intellinetics. In fact, even before contract signing we were already jointly working on client proposals. The Intellivue™ platform fills a void in the market for those clients who can only afford to spend under $100,000 for an ECM solution. I expect to see multiple client relationships as a result of this exciting new Channel Partner.”

About ImageSoft, Inc.

ImageSoft, Inc. is a leading provider of tailored technology solutions to automate, streamline and improve workplace processes, and thereby, increase productivity, reduce operating costs and save time and money. Its markets include insurance companies, government, the courts, healthcare and educational institutions, and manufacturers. Founded in 1996, ImageSoft serves customers throughout the U.S., Canada and Mexico. An award winning company, in 2009 and 2008, ImageSoft was selected as one of Inc. Magazine’s Fastest-Growing Privately Held Companies and was named one of Michigan’s Economic Bright Spots by Corp! Magazine. Additionally, in 2008, it was cited as a Michigan 50 Companies to Watch by the Edward Lowe Foundation and, since 2007, has been named one of Metropolitan Detroit’s 101 Best and Brightest Companies to Work For. For additional information, please visit the Company’s corporate website: www.imagesoftinc.com

About GlobalWise Investments, Inc.

GlobalWise Investments, Inc., via its wholly owned subsidiary Intellinetics, Inc., is a Columbus, Ohio based Enterprise Content Management (ECM) pioneer with industry-leading software that delivers cloud ECM based solutions on-demand. The Company’s flagship platform, Intellivue™, represents a new industry benchmark and game-changing solution by enabling clients to access and manage the content of every scanned document, file, spreadsheet, email, photo, audio file or video tape — virtually anything that can be digitized — in their enterprise from any PC, laptop, tablet or smartphone from anywhere in the world.

For additional information, please visit the Company’s corporate website: www.GlobalWiseInvestments.com

This press release may contain “forward-looking statements.” Expressions of future goals and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements may include, without limitation, statements about our market opportunity, strategies, competition, expected activities and expenditures as we pursue our business plan. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot predict the effect that market conditions, customer acceptance of products, regulatory issues, competitive factors, or other business circumstances and factors described in our filings with the Securities and Exchange Commission may have on our results. The company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this press release.

GlobalWise Investments, Inc.
www.GlobalWiseInvestments.com
614-388-8909
Contact@GlobalWiseInvestments.com

Mission Investor Relations
Atlanta, Georgia
http://www.MissionIR.com
404-941-8975
Investors@MissionIR.com

AxoGen, Inc. (AXGN) Poised For Strong Growth In Regenerative Medicine

The following article was recently posted to Seeking Alpha by Cockrell Group. To view the original source, please click the following link: http://seekingalpha.com/instablog/1766851

Nerve damaging injuries and surgeries can lead to a life of despair for the patient, leaving them with limited, or no, ability to move or even experience the feeling of touch. Recent advances in the field of regenerative medicine are giving hope to those suffering the debilitating effects of nerve injuries. As an emerging player in the area, AxoGen Inc. (AXGN) is poised to significantly contribute to this cutting-edge science.

Regenerative medicine enables the repair, restoration or replacement of tissue or organ systems of the body. Peripheral nerves provide the pathways for both motor and sensory signals between the central nervous system and target organs, regulating movement and touch. Traditionally, when peripheral nerves are damaged, patients have been presented with few medical options that offer meaningful recoveries.

AxoGen’s proprietary products give surgeons new alternatives to repair damaged peripheral nerves. The company’s products include AxoGuard® Nerve Connector, AxoGuard® Nerve Protector and Avance® Nerve Graft. AxoGuard® Nerve Connector is a coaptation aid to reconnect severed nerves, and AxoGuard® Nerve Protector protects nerves as the body heals after surgery. Avance® Nerve Graft, which is regarded as the first and only commercially available processed nerve allograft, bridges nerve gaps in severed nerves.

Hundreds of peripheral nerve injuries occur every day as a result of car crashes, power tool accidents and military combat. AxoGen’s products position it to be able to tap into this large and growing peripheral nerve repair market.

Ladenburg Thalmann & Co., Inc. analyst Jeffrey Cohen stated, “We would currently estimate that there are approximately 140,000 to 180,000 annual [autograph] procedures of the sural nerve in the United States. Coupled with other potential indications for usage, we believe that the market size for Avance in the U.S. to be approximately $500 million. The market for the rest of world could potentially double the size of the market.”

Patients who suffer from these types of injuries, which number more than 700,000 a year, have had few options for a meaningful recovery. These challenging injuries have traditionally been repaired by surgeons who transplant a healthy nerve from another area in the patient’s body to the nerve repair site. This creates an additional procedure that can lead to scarring, potential loss of feeling and pain in the area from which the nerve was removed. AxoGen’s products do away with these issues.

The Avance® Nerve Graft was recently the topic of a clinical study led by The Buncke Clinic in San Francisco. Called the RANGER study, it included 12 centers and 25 surgeons making it the largest multi-center study in peripheral nerve reconstruction. The findings were published in the January 2012 issue of study.

The principal investigator for the study was Dr. Darrell Brooks, a plastic surgeon with The Buncke Clinic. Calling the clinical study results a ‘paradigm shift,’ Brooks noted that the information he now uses to counsel his patients before their surgeries will change.

“It is commonly accepted among surgeons who do peripheral nerve repair that success of surgery depends on the type of injury, length of nerve discontinuity, the patient’s age and the type of nerve,” Dr. Brooks has stated. “Our study findings show that with processed nerve allograft, patients can have meaningful recovery regardless of these factors.”

There were no reported implant complications, tissue rejections or adverse events related to the use of the processed nerve allografts. Trial participants included subjects from Level 1 trauma centers, academic medical centers, military medical centers and community medical centers.

To further boost its presence in the regenerative medical field, AxoGen last year merged with LecTec. Although there were increased expenses as a result of the merger that contributed to an operating loss of $9.2 million for 2011, the company’s revenues and gross profit increased. Revenues increased 61% to $4.9 million in 2011 compared to 2010. The company’s gross profit increased 49% to $2.4 million for the same period.

AxoGen is poised to continue to improve its financial results. It has committed to specific growth areas, including investing in its sales force and expanding clinical and scientific data regarding the performance of its products.

Moving forward, the company intends to use its capital resources to continue to improve shareholder value with focused commercialization strategies to increase awareness and adoption of the new regenerative medicine technologies for peripheral nerve repair.

Jeffrey Cohen initiated coverage on AxoGen shares with a BUY rating and a target price of $4.50 in January 2012. That price is based on a discounted fiscal 2013 Enterprise Value to Revenue (EV/R) multiple compared to several of AxoGen’s peers.

As of the time of writing, the company was trading at $2.70.

Over a series of articles, the impact of AxoGen’s products will be examined. This includes the story of a 10-year old boy who suffered nerve damage to his arm after an ATV accident.